# Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

> **NCT00970268** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 291 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Aclidinium bromide

## Key facts

- **NCT ID:** NCT00970268
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970268, "Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00970268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*